# Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis

> **NCT02664649** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 1510 (estimated)

## Conditions studied

- Symptomatic Aortic Stenosis
- Eligible for Transcatheter Aortic Valve Replacement

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT02664649
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-26
- **Primary completion:** 2020-10-15
- **Final completion:** 2020-10-15
- **Target enrollment:** 1510 (ESTIMATED)
- **Last updated:** 2021-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02664649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02664649, "Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02664649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*